119 related articles for article (PubMed ID: 36379207)
21. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
22. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors.
Rivas EI; Linares J; Zwick M; Gómez-Llonin A; Guiu M; Labernadie A; Badia-Ramentol J; Lladó A; Bardia L; Pérez-Núñez I; Martínez-Ciarpaglini C; Tarazona N; Sallent-Aragay A; Garrido M; Celià-Terrassa T; Burgués O; Gomis RR; Albanell J; Calon A
Nat Commun; 2022 Sep; 13(1):5310. PubMed ID: 36085201
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.
Shi Y; Fan X; Deng H; Brezski RJ; Rycyzyn M; Jordan RE; Strohl WR; Zou Q; Zhang N; An Z
J Immunol; 2015 May; 194(9):4379-86. PubMed ID: 25795760
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tural D; Serdengecti S; Demirelli F; Öztürk T; İlvan S; Turna H; Özgüroglu M; Büyükünal E
Br J Cancer; 2014 Apr; 110(8):1968-76. PubMed ID: 24595002
[TBL] [Abstract][Full Text] [Related]
25. 3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.
Gangadhara S; Smith C; Barrett-Lee P; Hiscox S
BMC Cancer; 2016 Jun; 16():345. PubMed ID: 27251376
[TBL] [Abstract][Full Text] [Related]
26. Recognition and activation of Rho GTPases by Vav1 and Vav2 guanine nucleotide exchange factors.
Heo J; Thapar R; Campbell SL
Biochemistry; 2005 May; 44(17):6573-85. PubMed ID: 15850391
[TBL] [Abstract][Full Text] [Related]
27. Charge variant analysis of proposed biosimilar to Trastuzumab.
Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
[TBL] [Abstract][Full Text] [Related]
28. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
29. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.
Norton N; Olson RM; Pegram M; Tenner K; Ballman KV; Clynes R; Knutson KL; Perez EA
Cancer Immunol Res; 2014 Oct; 2(10):962-9. PubMed ID: 24989892
[TBL] [Abstract][Full Text] [Related]
30. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
31. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.
Bartel CA; Jackson MW
PLoS One; 2017; 12(5):e0176778. PubMed ID: 28463969
[TBL] [Abstract][Full Text] [Related]
32. The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration.
Ojala VK; Knittle AM; Kirjalainen P; Merilahti JAM; Kortesoja M; Tvorogov D; Vaparanta K; Lin S; Kast J; Pulliainen AT; Kurppa KJ; Elenius K
J Biol Chem; 2020 Aug; 295(33):11559-11571. PubMed ID: 32561640
[TBL] [Abstract][Full Text] [Related]
33. PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.
Pandya K; Wyatt D; Gallagher B; Shah D; Baker A; Bloodworth J; Zlobin A; Pannuti A; Green A; Ellis IO; Filipovic A; Sagert J; Rana A; Albain KS; Miele L; Denning MF; Osipo C
Clin Cancer Res; 2016 Jan; 22(1):175-86. PubMed ID: 26350262
[TBL] [Abstract][Full Text] [Related]
34. Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III.
Corrales-Aguilar E; Trilling M; Hunold K; Fiedler M; Le VT; Reinhard H; Ehrhardt K; Mercé-Maldonado E; Aliyev E; Zimmermann A; Johnson DC; Hengel H
PLoS Pathog; 2014 May; 10(5):e1004131. PubMed ID: 24830376
[TBL] [Abstract][Full Text] [Related]
35. VAV2, a guanine nucleotide exchange factor for Rac1, regulates glucose-stimulated insulin secretion in pancreatic beta cells.
Veluthakal R; Tunduguru R; Arora DK; Sidarala V; Syeda K; Vlaar CP; Thurmond DC; Kowluru A
Diabetologia; 2015 Nov; 58(11):2573-81. PubMed ID: 26224100
[TBL] [Abstract][Full Text] [Related]
36. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.
Pedersen MW; Jacobsen HJ; Koefoed K; Dahlman A; Kjær I; Poulsen TT; Meijer PJ; Nielsen LS; Horak ID; Lantto J; Kragh M
Mol Cancer Ther; 2015 Mar; 14(3):669-80. PubMed ID: 25612619
[TBL] [Abstract][Full Text] [Related]
37. White blood cell subsets in HER2-positive breast cancer patients treated with trastuzumab in relation to clinical outcome.
Matić IZ; Grujić M; Kolundžija B; Damjanović A; Tomašević Z; Đorđić Crnogorac M; Džodić R; Filipović Lješković I; Ždrale Z; Erić-Nikolić A; Juranić Z
Pathol Res Pract; 2021 Aug; 224():153543. PubMed ID: 34273805
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
39. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.
Aghazadeh S; Yazdanparast R
Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367
[TBL] [Abstract][Full Text] [Related]
40. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
